Recombinant adenoviral vectors and their utility in the treatment of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars
AssigneeTGT Laboratories, S.A. DE C.V.
InventorsJuan Armendariz Borunda, Estuardo Aguilar Cordova
Life of this patent
Estimating the term…
Abstract
The present invention relates to recombinant adenoviral vectors bearing exogenous genes that encode for therapeutic proteins useful in the treatment of hepatic cirrhosis and generalized fibrosis, such as renal fibrosis, pulmonary fibrosis, hypertrophic scars and keloid of the skin, and/or in other target organs susceptible to suffer from it. The invention also relates to a mechanism of tissue-specific recognition of the affected cells by means of delivery of therapeutic genes to cirrhotic organs.
Claims3
A recombinant adenoviral vector contained in ATCC Deposit No. PTA-10532, wherein the recombinant adenoviral vector encodes a latent human metalloprotease MMP-8 under the control of a cytomegalovirus (CMV) promoter.
Dependencies are inferred from the claim text.